Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024
Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies
Be Biopharma Expands Leadership Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced that Chief Executive Officer Joanne Smith-Farrell,Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, CA on Wednesday, January 10, 2024.
Be Bio Announces Data Showing BE-101 Produces Active Levels of Factor IX
Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX
Be Biopharma Presents Data Showing B Cell Medicines Produce Antitumor Biologics
Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa